

Virtual Expanded Access Program providing breast cancer patients early access to sub-Q treatment during COVID-19 pandemic



CLIENT NEED

- Enable **continuity of care** during the COVID-19 pandemic to breast cancer patients by providing rapid access to an alternate administration method for maintenance therapy
- Provide a solution where patients **do not need to visit brick and mortar facilities** for early access program study conduct across 400 US breast cancer patients ahead of commercial availability
- **Speed to patient access** was of critical importance to continue to treat patients as safely as possible during the COVID-19 pandemic



APPROACH

- **Collaborative and motivated customer** driving internal activities and decisions to facilitate speed
- Partner with **Science 37** for **integrated solution** to enable brick and mortar sites to support patients virtually
- **Academic medical center** site activation enabled through **expedited IRB approvals and contracts**
- **Immediate engagement** of PPD execution team to ensure speed of start-up



BENEFITS

- ✔ First patient to be dosed within **one month** of start with engaged team and PPD partnership and single platform solution with Science 37
- ✔ Virtual approach **mitigates risk to patient safety** in the COVID-19 pandemic and enables early patient access to sub-q formulation

Virtual study expertise inform collaborative study engineering, protocol and ICF development and review

Science 37 Metasite resources study coordinators and mobile nurses to facilitate patient visits, data collection and direct to patient clinical supplies and administration



Science 37 platform digitally enables with eConsent, eSource, EDC, ePRO and video telemedicine

Committed virtual, study, site and safety management **team** and **expedited site activation**